Talk:Canada's Drug Agency
![]() | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||||
|
Copyright review.
editThis article was much too close to the source. I reverted to a version before text was copied or closely paraphrased from it.--SPhilbrick(Talk) 17:19, 2 April 2013 (UTC)
Talk: Proposed Content for CADTH Wiki Page
editMandate
CADTH is Canada’s drug and health technology agency. It was established by Canada’s federal, provincial, and territorial governments in 1989 to be a trusted source of independent information and advice for the country’s publicly funded health care systems.
Role
Health administrators and policy experts rely on CADTH to help inform their decisions about the life cycle management of the drugs, devices, and services used to prevent, diagnose, and treat medical conditions.
CADTH Products and Services
Each year, CADTH responds to hundreds of evidence requests. In general, CADTH’s work can be grouped into the following evidence product categories:
- Horizon Scans: CADTH scans the horizon and alerts health care systems about new or emerging health technologies that could impact the delivery of care in Canada.
- Reference Lists: CADTH’s team of medical librarians searches the published and unpublished (i.e., grey) literature to identify the available evidence as well as any gaps in the scientific literature.
- Health Technology Reviews: CADTH provides decision-makers with independent assessments of drugs and other health technologies. Assessments consist of one, or a combination, of the following: an environmental scan, a rapid review, a clinical (or systematic) review, an economic review, or a review of patient perspectives. They may also include an assessment of the legal, ethical, social, implementation, environmental, and policy implications of a specific health technology. Recommendations on the appropriate use of health technologies are provided where applicable.
- Reimbursement Reviews: CADTH provides drug funding recommendations to Canada’s federal, provincial, and territorial public drug programs. Recommendations are based on comprehensive assessments of the clinical and pharmacoeconomic evidence, as well as input from pharmaceutical companies, clinicians, and patient groups. Recommendations cover oncology drugs, non-oncology drugs, plasma protein products, and CAR-T and gene therapies. Where appropriate, CADTH recommends the appropriate place in therapy for drugs within a therapeutic class.
- Scientific Advice: CADTH offers pharmaceutical companies advice on their early drug development plans from a health technology assessment perspective. CADTH Scientific Advice helps industry optimize the time to market for new therapies.
CADTH Overview
Governance
CADTH is an independent, not-for-profit organization. Its 13-member Board of Directors is composed of an independent chair; a regional distribution of federal, provincial, and territorial representatives; and non-jurisdictional representatives from health systems, academia, and the public. Directors are elected by the Members of the Corporation, who are the Deputy Ministers of Health for participating federal, provincial, and territorial governments.
Websites
Canadian Journal of Health Technologies
Strategic Plan
Annual Report
Location
Offices in Ottawa (headquarters) and Toronto, with staff located in every province and the Yukon
CEO
Suzanne McGurn 142.112.208.13 (talk) 22:18, 21 February 2023 (UTC)
CADTH logo
editCan we put the logo for the article? 74.14.0.195 (talk) 06:20, 18 April 2024 (UTC)
- Can someone put the logo for Canada’s drug agency? It’s literally just cda amc 184.144.90.12 (talk) 23:32, 2 June 2024 (UTC)